Integra Lifesciences Holdings Corp (NASDAQ:IART) Expected to Announce Quarterly Sales of $376.60 Million

Share on StockTwits

Analysts expect that Integra Lifesciences Holdings Corp (NASDAQ:IART) will report $376.60 million in sales for the current quarter, according to Zacks Investment Research. Five analysts have provided estimates for Integra Lifesciences’ earnings, with the highest sales estimate coming in at $377.00 million and the lowest estimate coming in at $376.35 million. Integra Lifesciences reported sales of $365.85 million in the same quarter last year, which indicates a positive year over year growth rate of 2.9%. The company is scheduled to announce its next earnings report before the market opens on Thursday, October 24th.

On average, analysts expect that Integra Lifesciences will report full-year sales of $1.52 billion for the current financial year. For the next year, analysts expect that the firm will post sales of $1.60 billion, with estimates ranging from $1.59 billion to $1.61 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that cover Integra Lifesciences.

Integra Lifesciences (NASDAQ:IART) last posted its quarterly earnings data on Wednesday, July 24th. The life sciences company reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.08. Integra Lifesciences had a return on equity of 16.30% and a net margin of 6.76%. The company had revenue of $383.60 million during the quarter, compared to analysts’ expectations of $373.29 million. During the same period in the prior year, the business earned $0.60 earnings per share. Integra Lifesciences’s revenue for the quarter was up 4.8% compared to the same quarter last year.

Several equities research analysts have recently weighed in on the company. Zacks Investment Research raised Integra Lifesciences from a “hold” rating to a “buy” rating and set a $65.00 price objective for the company in a research report on Monday, September 2nd. Wells Fargo & Co reduced their price objective on Integra Lifesciences from $68.00 to $65.00 and set a “market perform” rating for the company in a research report on Tuesday. Oppenheimer increased their price objective on Integra Lifesciences from $65.00 to $70.00 and gave the company an “outperform” rating in a research report on Thursday, July 25th. ValuEngine cut Integra Lifesciences from a “hold” rating to a “sell” rating in a research report on Thursday, August 1st. Finally, JMP Securities increased their price objective on Integra Lifesciences to $75.00 in a research report on Thursday, July 25th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $62.42.

In related news, VP Daniel L. Reuvers sold 5,000 shares of the firm’s stock in a transaction on Wednesday, July 24th. The stock was sold at an average price of $60.00, for a total value of $300,000.00. Following the completion of the transaction, the vice president now directly owns 35,392 shares of the company’s stock, valued at $2,123,520. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Glenn Coleman sold 3,500 shares of the firm’s stock in a transaction on Wednesday, July 24th. The stock was sold at an average price of $57.50, for a total value of $201,250.00. Following the completion of the transaction, the chief operating officer now directly owns 35,194 shares of the company’s stock, valued at $2,023,655. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 887,921 shares of company stock valued at $54,121,075. 4.50% of the stock is owned by company insiders.

A number of institutional investors have recently added to or reduced their stakes in the business. Boston Partners raised its stake in Integra Lifesciences by 1.3% during the second quarter. Boston Partners now owns 13,119 shares of the life sciences company’s stock worth $733,000 after acquiring an additional 171 shares in the last quarter. Municipal Employees Retirement System of Michigan raised its stake in Integra Lifesciences by 1.5% during the second quarter. Municipal Employees Retirement System of Michigan now owns 13,080 shares of the life sciences company’s stock worth $731,000 after acquiring an additional 190 shares in the last quarter. Zions Bancorporation N.A. raised its stake in Integra Lifesciences by 5.9% during the second quarter. Zions Bancorporation N.A. now owns 4,359 shares of the life sciences company’s stock worth $243,000 after acquiring an additional 242 shares in the last quarter. LPL Financial LLC raised its stake in Integra Lifesciences by 4.4% during the second quarter. LPL Financial LLC now owns 5,754 shares of the life sciences company’s stock worth $319,000 after acquiring an additional 242 shares in the last quarter. Finally, Advisor Group Inc. raised its stake in Integra Lifesciences by 0.9% during the first quarter. Advisor Group Inc. now owns 30,842 shares of the life sciences company’s stock worth $1,719,000 after acquiring an additional 282 shares in the last quarter. Hedge funds and other institutional investors own 81.83% of the company’s stock.

Shares of IART traded up $1.70 during mid-day trading on Friday, hitting $60.83. The company’s stock had a trading volume of 18,498 shares, compared to its average volume of 352,463. Integra Lifesciences has a one year low of $42.14 and a one year high of $65.09. The company has a debt-to-equity ratio of 0.99, a quick ratio of 1.82 and a current ratio of 2.76. The firm has a market capitalization of $4.96 billion, a PE ratio of 25.14, a price-to-earnings-growth ratio of 1.79 and a beta of 1.10. The stock’s 50-day moving average is $60.23 and its two-hundred day moving average is $55.73.

Integra Lifesciences Company Profile

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Read More: How Do Tariffs Affect Trade Balances?

Get a free copy of the Zacks research report on Integra Lifesciences (IART)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.